IL178042D0 - Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation - Google Patents

Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Info

Publication number
IL178042D0
IL178042D0 IL178042A IL17804206A IL178042D0 IL 178042 D0 IL178042 D0 IL 178042D0 IL 178042 A IL178042 A IL 178042A IL 17804206 A IL17804206 A IL 17804206A IL 178042 D0 IL178042 D0 IL 178042D0
Authority
IL
Israel
Prior art keywords
antibodies
cancer cell
cell proliferation
inhibit cancer
inhibit
Prior art date
Application number
IL178042A
Other versions
IL178042A (en
Original Assignee
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US55642204P priority Critical
Priority to US55642104P priority
Priority to US62504904P priority
Priority to US65109805P priority
Priority to US65751405P priority
Priority to PCT/US2005/009939 priority patent/WO2005092073A2/en
Application filed by Pdl Biopharma Inc filed Critical Pdl Biopharma Inc
Publication of IL178042D0 publication Critical patent/IL178042D0/en
Publication of IL178042A publication Critical patent/IL178042A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
IL178042A 2004-03-24 2006-09-12 Pharmaceutical compositions containing anti-alpha5beta1 antibodies for inhibiting cancer cell proliferation IL178042A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US55642204P true 2004-03-24 2004-03-24
US55642104P true 2004-03-24 2004-03-24
US62504904P true 2004-11-03 2004-11-03
US65109805P true 2005-02-07 2005-02-07
US65751405P true 2005-02-28 2005-02-28
PCT/US2005/009939 WO2005092073A2 (en) 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Publications (2)

Publication Number Publication Date
IL178042D0 true IL178042D0 (en) 2006-12-31
IL178042A IL178042A (en) 2011-05-31

Family

ID=35056776

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178042A IL178042A (en) 2004-03-24 2006-09-12 Pharmaceutical compositions containing anti-alpha5beta1 antibodies for inhibiting cancer cell proliferation

Country Status (15)

Country Link
US (2) US7662384B2 (en)
EP (1) EP1755659B1 (en)
JP (1) JP4857259B2 (en)
KR (1) KR20070009637A (en)
AT (1) AT531388T (en)
AU (1) AU2005226736B2 (en)
BR (1) BRPI0509177A (en)
CA (1) CA2560508A1 (en)
DK (1) DK1755659T3 (en)
ES (1) ES2376556T3 (en)
HK (1) HK1101348A1 (en)
IL (1) IL178042A (en)
NO (1) NO20064794L (en)
NZ (1) NZ549893A (en)
WO (1) WO2005092073A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645810C (en) 2006-03-15 2018-12-11 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
NZ615012A (en) * 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
WO2007114851A1 (en) * 2006-04-04 2007-10-11 The Board Of Trustees Of The University Of Illinois Methods and compositions to induce cell death of invasive tumors
WO2007134876A2 (en) * 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
JP2010534685A (en) * 2007-07-27 2010-11-11 ファセット バイオテック コーポレイション Pharmaceutical combination comprising a tyrosine kinase inhibitor and an antibody against integrin α5β1 (CD49E)
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
EP2641612A1 (en) 2008-02-05 2013-09-25 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
JP2012513194A (en) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ Targeted binding agents directed to α5β1 and uses thereof
MX2011010012A (en) 2009-03-25 2011-12-06 Genentech Inc Novel anti-î+-5î²1 antibodies and uses thereof.
AU2012328739B2 (en) 2011-10-25 2017-11-30 Prothena Biosciences Limited Antibody formulations and methods
US8946159B2 (en) 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
NO2760138T3 (en) 2012-10-01 2018-08-04

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704366A (en) * 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
JPS61134325A (en) * 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
KR100240308B1 (en) * 1991-03-06 2000-01-15 플레믹 크리스티안 Humanized and chimeric monoclonal antibodies
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
CA2130436C (en) * 1992-02-19 2001-04-10 John S. Abrams Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP3490443B2 (en) 1992-10-29 2004-01-26 ジ・オーストラリアン・ナショナル・ユニバーシティ Anti-angiogenic antibody
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
EP0704920B1 (en) * 1994-09-21 2000-04-19 Matsushita Electric Industrial Co., Ltd. Solid-state lithium secondary battery
JP2001527513A (en) 1996-03-15 2001-12-25 デュポン ファーマシューティカルズ カンパニー Spirocyclic integrin inhibitors
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
WO1998032771A1 (en) 1997-01-29 1998-07-30 Toray Industries, Inc. Chimeric proteins, heterodimer complexes thereof and substitute for platelet
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6495319B1 (en) 1998-04-27 2002-12-17 Sidney Kimmel Cancer Center Reduced complexity nucleic acid targets and methods of using same
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP2327451B1 (en) * 1998-05-08 2013-10-23 The Regents of the University of California Method for detecting and inhibiting angiogenesis
JP2003517816A (en) 1999-08-11 2003-06-03 イオス バイオテクノロジー， インコーポレイテッド Novel methods of diagnosing angiogenesis, compositions and methods of screening for angiogenic regulators
WO2001053297A1 (en) 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2001053262A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
JP2004531249A (en) 2001-02-14 2004-10-14 プロテイン デザイン ラブス インコーポレイティド Method for diagnosing angiogenesis, composition, and method for screening angiogenesis modulator
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
RU2346701C2 (en) * 2002-11-26 2009-02-20 ПиДиЭл БАЙОФАРМА ИНК. CHIMERIC AND HUMANISED INTEGRIN α5β1 ANTIBODIES MODULATING ANGIOGENESIS
US20050002930A1 (en) * 2003-04-03 2005-01-06 Johnson Dale E. Methods of production and use of anti-integrin antibodies for the control of tissue granulation
JP4703566B2 (en) 2003-05-14 2011-06-15 イムノゲン インコーポレーティッド Drug complex composition

Also Published As

Publication number Publication date
JP4857259B2 (en) 2012-01-18
AU2005226736A1 (en) 2005-10-06
EP1755659A2 (en) 2007-02-28
AT531388T (en) 2011-11-15
DK1755659T3 (en) 2012-02-27
US20050260210A1 (en) 2005-11-24
US7662384B2 (en) 2010-02-16
WO2005092073A2 (en) 2005-10-06
EP1755659B1 (en) 2011-11-02
AU2005226736B2 (en) 2009-11-26
KR20070009637A (en) 2007-01-18
NO20064794L (en) 2006-10-23
JP2007530584A (en) 2007-11-01
NZ549893A (en) 2010-05-28
IL178042A (en) 2011-05-31
ES2376556T3 (en) 2012-03-14
HK1101348A1 (en) 2007-10-18
EP1755659A4 (en) 2008-08-20
BRPI0509177A (en) 2007-09-18
US20100291111A1 (en) 2010-11-18
CA2560508A1 (en) 2005-10-06
WO2005092073A3 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
HK1220839A1 (en) Distribution of content
IL257290D0 (en) Antibodies to il-6 and use thereof
IL271270D0 (en) Antibodies to il-6 and use thereof
GB2456592B (en) Techniques to improve time seek operations
DK1730191T3 (en) Immunoglobulin Binding to HOSM
IL219890A (en) Anti-idiotype antibodies binding to il-23p19 antibodies
IL199836D0 (en) Human cancer stem cells
AT528300T (en) Bicyclic compounds and their use as antidiabetika
IL212985D0 (en) Therapeutic uses of inhibitors of rtp801
EP1778831A4 (en) Genetically modified host cells and use of same for producing isoprenoid compounds
ZA200702827B (en) Group details of group services
PL1636190T3 (en) Stable crystal of 4-oxoquinoline compound
AT477495T (en) Biological markers predictive for the application of cancer to inhibitors of the cinema of the receptor for epidermal growth factor
AT455181T (en) Biochemical synthesis of 6-aminocapronic acid
RU2005127417A (en) Internal structure of rfid-cepbepa
EP1768190A4 (en) Photoelectrochemical cell
DK1802872T3 (en) Construction of gasline
HK1124622A1 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti- fucosyl-gm1
AT438417T (en) Improvements related to skin associations
ZA200901402B (en) Antibodies to il-17a
ZA200900395B (en) Antibodies directed to +-Vß6 and uses thereof
EP1734995A4 (en) Monoclonal antibodies to hepatocyte growth factor
HK1164320A1 (en) Synthesis of bortezomib
GB0412277D0 (en) Antenna structure
EP2226212A4 (en) Cooling-air-intake structure of battery

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees